Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non-Small Cell Lung
Haruki Kobayashi1, Kazushige Wakuda1, Tateaki Naito2
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan; Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, Japan.
Introduction/Background:
The proper duration of immune checkpoint inhibitor (ICI) treatment for patients with advanced non-small cell lung cancer (NSCLC) remains unclear. Previously, sponsor-initiated clinical trials have more often used either a maximum 2-year fixed duration of ICI treatment or continuous treatment until documented disease progression. The study aimed to evaluate the association between ICI treatment duration (2-year fixed or continuous) and prognosis in patients with advanced NSCLC.
Patients And Methods:
The medical records of 425 patients with NSCLC who received ICI before August 31, 2019 were retrospectively reviewed.
Results:
No differences in time to treatment failure > 24 months (TTF-24) were detected between patients who underwent ICI treatment for > 2 years and patients who stopped ICI treatment at 2 years. Treatment-related adverse events tended to be higher in the patients with ICI treatment > 2 years.
Conclusion:
ICI treatment > 2 years did not significantly prolong the TTF compared with ICI treatment = 2 years, but it did increase the incidence of treatment-related adverse events.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers